Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Year's First 4 IPOs Go South As Proteostasis, AveXis Launch

This article was originally published in Scrip

Executive Summary

Biotechnology has been the only industry to launch initial public offerings in the US in 2016, and based on the performance of the four drug makers' stocks so far, they may be the only biotech firms to go public this year.

Advertisement

Related Content

IPO Update: TiGenix Debuts In December After Motif Launched In November As 2016 Offerings Best 2015
Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments

Topics

Advertisement
UsernamePublicRestriction

Register

SC064491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel